Source: Organigram.
  • Organigram, one of Canada’s first cannabis stocks, is announcing an overnight marketed public offering of units for up to C$25 million
  • The offering seeks to capitalize on a sector-wide bump in cannabis stocks after Germany’s passing of legislation to legalize recreational cannabis beginning April 1
  • Organigram is a licensed producer of cannabis flower, edibles and other derived products for the Canadian recreational and medical markets
  • Organigram stock has given back 17.15 per cent year-over-year, and has lost 92.08 per cent of its value over the past five years

Organigram (TSX:OGI), one of Canada’s first cannabis stocks, is announcing an overnight marketed public offering of units for up to C$25 million.

The company intends to use the net proceeds for growth initiatives and general corporate purposes.

ATB Securities will serve as lead underwriter, on behalf of itself and a syndicate of underwriters, for the sale of 7,740,000 units at a price of C$3.23 per unit. Each unit is composed of one Organigram common share and one half of one common share purchase warrant, while each warrant is exercisable to acquire one common share for C$3.65 for four years after the closing of the offering. The offering is expected to close on or about April 2, 2024.

An over-allotment option, exercisable in whole or in part, allows the underwriters to purchase up to an additional 1,161,000 units at the offering price for up to 30 days after the closing of the offering.

Potential investors can learn more about the offering by consulting the prospectus supplement to be filed with Canadian securities regulatory authorities on SEDAR and the U.S. Securities and Exchange Commission.

Capitalizing on a recent upswing in cannabis stocks

Organigram’s share offering coincides with a steep rise across cannabis stocks because of new legislation, passed by Germany’s parliament on March 22, that will legalize recreational cannabis country-wide as of April 1. Germany is the European Union’s largest economy and could take in more than US$5 billion in additional tax revenue per year from cannabis sales.

Key cannabis stocks closely monitored by Stockhouse readers have benefitted from the upward momentum:

Investors interested in expanding their exposure to cannabis can consult Stockhouse’s Weekly Cannabis Report, published every Friday, for fresh insights on recent industry news.

About Organigram

Organigram is a licensed producer of cannabis flower, edibles and other derived products for the Canadian recreational and medical markets. Its brand portfolio includes Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer.

Organigram stock (TSX:OGI) gained more than 15 per cent after Germany announced its new legislation. The stock has since fallen by 21.92 per cent after Wednesday’s offering notice, trading at C$2.85 per share as of 12:13 pm ET. OGI shares have given back 17.15 per cent year-over-year, and have lost 92.08 per cent of their value over the past five years.

Join the discussion: Learn what other investors are saying about this cannabis stock on the Organigram Inc. Bullboard, and check out Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
Cannabis Report text across cannabis leaves.

StockTalk | Cannabis Report: The Holiday Edition

MediPharm Labs has signed a share purchase agreement with Kensana Health for the purchase and sale of its facility in Napanee, Ontario.
Cannabis Report in text over top a photo of cannabis leaves

StockTalk | Cannabis Report: A new Canadian cannabis king crowned

Several TSX healthcare stocks that cater to various aspects of the healthcare market are listed on the TSX, including notable cannabis stocks
Man in cannabis field

Cannabis-based autism drug shines in phase-1 testing

Charlotte's Web (TSX:CWEB) announces positive results from a phase-1 dose trial of AJA001, its cannabis-based autism treatment.
File image of a snow drift

Buzz on the Bullboards: Feeling holiday blues, or celebrating blue chip stocks?

Some shareholders have enjoyed early holiday gifts in the form of rising stock prices, while others have faced disappointments.